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PURPOSE. The purpose of this study was to evaluate the effect of alendronates on bone remodeling around 
titanium implant in the maxilla of rats. MATERIALS AND METHODS. The maxillary first molars were extracted 
and customized-titanium implants were placed immediately in thirty male Sprague-Dawley rats. The rats were 
divided into experimental (bisphosphonate) group and control group. At 4 weeks after implantation, the rats in 
the bisphosphonate group were subcutaneously injected with alendronate three times a week for 6 weeks where 
as the rats in control group were injected with saline. The rats were sacrificed at 1, 2, 3, 4, or 6 weeks after 
starting of injection and maxillary bones were collected subsequently. Alveolar bone remodeling around the 
implants were evaluated by radiographic and histologic analysis. Microarray analysis and 
immunohistomorphologic analysis were also performed on one rat, sacrificed at 6 weeks after starting of 
injection, from each group. Statistical analysis was performed using repeated measures analysis of variance and 
independent t test at a significance level of 5%. RESULTS. There was no statistically significant difference in the 
bone area (%) around implant between the bisphosphonate group and the control group. However, the amount 
of empty lacuna was significantly increased in the bisphosphonate group, especially in the rats sacrificed at 4 
weeks after starting of injection compared to that of the corresponding control group. The bisphosphonate group 
showed the same level of TRAP positive cell count, osteocalcin and angiopoietin 1 as the control group. 
CONCLUSION. Alendronate may not decrease the amount of osteoclast. However, the significantly increased 
amount of empty lacuna in the bisphosphonate group may explain the suppression of bone remodeling in the 
bisphosphonate group. [ J Adv Prosthodont 2013;5:374-81]
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INTRODUCTION
Bisphosphonates are drugs used most commonly in the 
management of  bone metabolic abnormalities such as 
osteoporosis, Paget’s disease and even cancer-associated 
bone disease.1 It is well known from many previous studies 
that bisphosphonates reduce bone resorption effectively by 
hindering the function of  osteoclast as well as hydroxyapa-
tite breakdown. Despite this high clinical efficacy of  
bisphosphonates, several complications associated with 
bisphosphonates therapy such as osteonecrosis of  the jaw, 
atrial fibrillation, and hypocalcemia have been reported.1
Since Marx2 first had reported observing osteonecrosis 
in 36 patients who received intravenous bisphosphonates 
following dental treatment, many studies have been done to 
Corresponding author: 
Hong-Seok Moon
Department of Prosthodontics, Oral Science Research Center, Yonsei 
University College of Dentistry, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-
752, Republic of Korea
Tel. 82222283155: e-mail, hsm5@yuhs.ac
Received December 11, 2012 / Last Revision March 31, 2013 / Accepted 
April 22, 2013
© 2013  The Korean Academy of Prosthodontics
This is an Open Access article distributed under the terms of the Creative 
Commons Attribution Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original 
work is properly cited.
+Ran Park and Jee-Hwan Kim equally contributed to the works described in 
this manuscript.
This study was supported by a grant of the Korean Health Technology R&D 
Project, Ministry of Health & Welfare, Republic of Korea (A110411).
The Journal of Advanced Prosthodontics    375
investigate contributing factors for bisphosphonate-related 
osteonecrosis of  the jaw (BRONJ). In 2004, Ruggiero et al.3 
suggested that not only intravenous bisphosphonates but 
also oral bisphosphonates could be a contributing factor 
for BRONJ. While the mechanisms of  BRONJ have not yet 
been clarified, suppression of  remodeling, impairment of  
angiogenesis as well as infection have been suggested as 
causative mechanisms.4
Among possible local risk factors for BRONJ including 
dental extraction, dental implant placement and periodontal 
surgery involving osseous injury, which are all suggested by 
American Association of  Oral and Maxillofacial Surgeons, 
dental extraction has been one of  the most frequently 
reported risk factors for BRONJ and this is supported by 
numerous studies published in the past 5 years.5,6 However, 
the use of  bisphosphonates as a risk factor for developing 
BRONJ following implant therapy is not elucidated and still 
controversial despite increased use of  dental implant these 
days. 
Recently, several studies have reported that BRONJ is 
strongly associated with reduced bone turnover rate during 
bone remodeling phase which is a normal process taking 
place after a successful osseointegration. Allen and Burr4 
insisted in their animal study with 3 years of  daily oral 
bisphosphonate treatment that necrosis results from the 
suppression of  bone matrix removal due to bisphospho-
nate-induced turnover suppression, assuming that there 
always is equilibrium between rate of  bone matrix forma-
tion and removal under normal conditions. Lazarovici et al. 7 
have reported of  the 11 patients, who received oral bis-
phosphonates, 6 patients developed BRONJ during the first 
6 months after implant placement. Interestingly, BRONJ 
was also developed in 5 patients during bone remodeling 
phase. On the other hand, Grant et al. 8 have reported that 
there was no evidence to support the effect of  oral 
bisphosphonate on survival rate of  implant. In their study, 
there was no significant difference in implant survival rate 
between patients who had received oral bisphosphonates 
and patients who had not received oral bisphosphonates. In 
addition to this controversy, most animal studies done 
regarding bone remodeling around dental implant was car-
ried out using long bones such as tibia or femur,9,10 which 
may not reflect the effect of  bisphosphonates on bone 
remodeling accurately. Since the overall rate of  turnover of  
alveolar bone is 10 times greater than that of  the long 
bones11 and the development and physiology of  the jaw 
bones are different from other bones,12-14 the effect of  
bisphosphonate on bone remodeling is required to be 
investigated in jaw bones. Moreover, although numerous 
studies have reported the effect of  bisphosphonates on 
immediate healing of  implant site, not many studies have 
addressed the effect of  bisphosphonates on remodeling of  
bone around implant site. Therefore, the purpose of  this 
study was to evaluate the effect of  bisphosphonate on bone 
remodeling around titanium implant in the maxilla of  rats.
MATERIALS AND METHODS
Thirty male Sprague-Dawley rats (body weight: 130-140 g; 
age: 4 weeks) were divided into the bisphosphonate group 
and control group and each group was subdivided into 5 
groups having 3 rats in each groups according to duration 
of  administration (1, 2, 3, 4 and 6 weeks). Animals were 
housed at the animal experimental laboratory at Yonsei 
University, College of  Dentistry, Seoul, Korea and allowed 
free access to food pellets and tap water. All experiments 
were performed in accordance with the guidelines for ani-
mal experiments of  Yonsei University College of  Dentistry. 
All surgical procedures involved in the study were con-
ducted under general anesthesia with a mixture of  Rumpun 
(xylazine, 20 mg/mL, 0.5 mL/kg body mass, Bayer, 
Leverkusen, Germany) and Zoletil (tiletamine and zolaze-
pam, 100 mg/mL, 0.5 mL/kg body mass; Virbac, Carros, 
France) via intramuscular injection.15 After maxillary right 
first molar was extracted using hemostat, osteotomy was 
performed with a 1.8 mm diameter bur in the extraction 
sockets of  the mesial roots (the largest root), followed by 
implantation of  titanium mini-implant (ø 2.0 × 2.5 mm) 
(Fig. 2) until the top of  the mini-implant reached the 
peripheral bone. Osseointegration was expected to occur 
within the first four weeks after implant placement. The 
rats in bisphosphonate group were then subcutaneously 
injected with 1.0 mg/kg of  alendronates (Alendronate 
Sodium Salt, Merial Inc., Parramata, NSW, Australia) three 
times a week for 6 weeks whereas rats in control group 
were injected with saline. Rats were sacrificed administra-
tion by perfusion fixation with 4% paraformaldehyde at 1, 
2, 3, 4 or 6 weeks after initial administration (Fig. 1). 
All specimens were decalcified with 10% EDTA at 4℃ 
for 2 months. Prior to embedding of  the decalcified sam-
ples in paraffin wax, customized implant was removed and 
a	 series	 of 	 7	 μm	 sections	were	 then	 prepared.	The	 sec-
tioned specimens were stained with hematoxylin-eosin 
(H&E), Trichrome (Masson) using a kit (Sigma, St. Louis, 
MO, USA), and TRAP (tartrate-resistant acid phosphatase) 
stain using an acid phosphatase leukocyte kit (Sigma). The 
specimens were then observed under light microscope 
(Lieca DM 2500, Leica Microsystems, Wetzlar, Germany). 
The bone area (%) was measured and quantified in the 
interested area: the distal side of  implant surface, using 
Image Pro Plus 4.5 (Media Cybermetrics, Silver Spring, 
USA) (Fig. 3). The number of  osteocyte with empty lacuna 
was counted at the same area. TRAP positive cells, indica-
tive of  osteoclast, were also counted using IMT i-solution 
lite version 8.1 program (IMT i-solution Inc., Daejeon, Korea).
To evaluate the effect of  bisphosphonate on the expres-
sion of  DNA at the site of  peri-implant bone, microarray 
analysis was carried out for the rats sacrificed at 6 weeks 
after starting of  injection in both bisphosphonate and con-
trol group. The extracted tissue was stored in RNAlater 
Solutions (Ambion, Austin, TX, USA) and sent to Research 
and Development Division Korea Institute of  Toxicology. 
Microarray analysis were performed using Rat genome 230 
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2.0 array (Affymetrix, Santa Clara, CA, USA) and sample 
labeling, microarray hybridization, washing, and scanning 
were performed according to the manufacturer’s protocol 
(Affymetrix, Santa Clara, CA, USA).
In order to observe the change in function of  osteo-
blast and angiogenesis activity, the specimens were stained 
with angiopoietin 1 and osteocalcin antibody using angio-
poietin 1 antibody kit (abbiotec LLC, San Diego, CA, USA) 
and osteocalcin FL-100 kit (Santa cruz biotechnology, Santa 
Cruz, CA, USA) respectively. Stained specimens were observed 
under the light microscope.
Mean values and standard deviations of  bone area (%), 
number of  empty lacuna and number of  tartrate-resistant 
acid phosphatase (TRAP)-positive cell were calculated. The 
mean differences were verified with repeated measures 
analysis of  variance and independent t test with a signifi-
cance level of  5%. All calculations were performed using 
SPSS ver. 18.0 Program (SPSS ver. 18.0, IBM, NY, USA).
Fig. 1.  Experimental design.
Fig. 3.  The interested 
area in the distal side of 
implant surface.
RESULTS
Among the total 30 male Sprague-Dawley rats, one rat from 
control group (1 week) died during implant placement and 
two rats from each control group (3 weeks) and bisphos-
phonate group (6 weeks) also died during recovery period. 
The other rats appeared to be normal without any signifi-
cant complication. Microarray analysis was carried out on 
each sample selected from both control group (6 weeks) 
and bisphosphonate group (6 weeks). For this reason, the 
rats sacrificed at 6 weeks after starting of  injection in both 
bisphosphonate and control group were excluded from sta-
tistical analysis.
Osteoclast, osteoblast and marrow spaces including 
mesenchymal cell and blood vessels were identified around 
implant, indicating that bone remodeling around implant 
had occurred. Following H&E staining, the bone area was 
measured	within	300	μm	area	around	distal	side	of 	implant	
using light microscope at ×100 magnification and expressed 
as percentage (%). There was no significant difference 
between control group and bisphosphonate group in bone 
area (%). On comparing bone area (%) within control group 
and bisphosphonate group, no statistically significant differ-
ence was found according to duration of  administration. 
(Fig. 4) Similar bone area (48.2%) were observed in each 
rats sacrificed at 6 weeks after starting of  injection from 
both control group and bisphosphonate group although 
they are not included for statistical analysis.
Empty lacuna was counted at the same area where bone 
area measurement (%) was taken. It appeared that empty 
lacuna in bisphosphonate group increased with the time 
and,in particular, there was statistically significant difference 
between control group and bisphosphonate group in the 
rats sacrificed at 4 weeks after starting of  injection (4 week 
group) (Fig. 5 and Fig. 6). When comparing the number of  
empty lacuna within each group according to duration of  
administration, there was no significant difference within 
Fig. 2.  Customized mini 
implant used for this study.
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control group. However, within bisphosphonate group, the 
number of  empty lacuna in the rats sacrificed at 4 weeks 
after starting of  injection (4 week group) was statistically 
significantly greater than that of  the rats sacrificed at 1 
week after starting of  injection (1 week group). The rats 
sacrificed at 6 weeks after starting of  injection in bisphos-
phonate group showed the empty lacuna value of  17.1, 
which was slightly lower than that of  4 week group but 
slightly higher than those of  1, 2 and 3 week groups.
The number of  osteoclasts using TRAP staining were 
also counted at the same area and showed no significant 
difference between control group and bisphosphonate 
group. On comparing the number of  osteoclasts within 
control group and bisphosphonate group, there was no sig-
nificant difference according to duration of  administration 
(Fig. 7 and Fig. 8).
Fig. 5.  Empty lacuna count in H&E stained section (×100). 
White arrows indicate empty lacunas. (A) Control group of 
4-week administration of saline, (B) Bisphosphonate group 
of 4-week administration of bisphosphonate.
A                                               B
Fig. 6.  Empty lacuna cell count: Asterisk (*) indicates 
statistically significant difference between control group 
and bisphosphonate group (Cont: control group, Bispho: 
experimental group).
Fig. 8.  TRAP positive cell count (Cont: control group, 
Bispho: experimental group).
Fig. 7.  Histologic images of TRAP stained sections 
(×100). White arrows indicate TRAP positive cells. (A) 




Fig. 4.  Measurement of bone area (%) in distal side of 
implant (Cont: control group, Bispho: experimental 
group)
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Fig. 9.  Immnohistochemical staining of angiopoietin 1 
(×200). White arrows indicate stained angiopoietin 1 
(Cont: control group, Bispho: experimental group).





Fig. 10.  Immunohistochemical staining of osteocalcin 
(×200). White arrows indicate cytoplasm of osteoblast 
and margin of remodeling cavity (Cont: control group, 
Bispho: experimental group).






Table 1.  Microarray analysis
Up regulation Down regulation 
*Fgf9 (2.19) *Klf5 (-5.48)
*Sost (2.94) Ceacam1 (-3.62)
*Bmp2 (2.01) *Pitx1 (-6.82)
*IL1β (8.73) *Angptl2 (-1.17)
The result shows prominent disparity of experimental (bisphosphonate) group 
compared to control group. 
*Fgf9: fibroblast growth factor 9, *Klf5: Kruppel-like factor 5,*Sost: sclerostin, 
*Bmp2: bone morphogenetic protein 2,*Pitx1: paired-like homeodomain 
transcription factor 1, *IL1β: Interleukin 1beta, *Angptl2: Angiopoietin-like 2.
Microarray analysis was carried out for the rats sacri-
ficed at 6 weeks after starting of  injection in both bisphos-
phonate and control group. The result of  up- and down- 
regulated genes in bisphosphonate group in comparison to 
that of  control group are shown in Table 1.
Immunohistochemical analysis revealed that both bis-
phosphonate and control group shows pattern of  staining 
along the wall of  blood vessel when stained with angiopoi-
etin 1 (Fig. 9). When stained with osteocalcin, which is bio-
marker of  osteoblast, the pattern of  staining was also iden-
tified at cytoplasm of  osteoblast and margin of  remodeling 
cavity in both bisphosphonate and control group (Fig. 10).
DISCUSSION
Rat model is widely used in many experimental animal 
model studies. According to previous report,16,17 in rat mod-
el, new bone formation and osseointergration was observed 
within 5 days and 28 days after implantation respectively. It 
was appeared that, after early osseointegration, bone remod-
eling phase is also taking place to promote remodeling and 
reinforcement of  bone surrounding implant. In this study, 
therefore, 4 weeks of  healing period (28 days) were allowed 
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to promote bone formation and osseointergration in the 
maxilla of  rats. Bisphosphonates were then injected at the 
point where bone remodeling phase are thought to be initi-
ated.The volume of  bisphosphonates injected (1.0 mg/kg 
of  alendronates) were determined as suggested by Hikita et 
al.5
From histologic findings, there was no significant differ-
ence in bone area (%) between control group and bisphos-
phonate group. However, the evaluation of  effect of  
bisphosphonate on bone remodeling by only measuring 
bone area (%) cannot be justified as the osteoclast activity 
is also reduced by bisphosphonate, hindering the break-
down of  bone. Moreover, it was also thought that period 
of  6 week administration could have been too short to 
quantify the suppression of  bone resorption into bone area 
(%). 
It was previously reported that empty lacuna formed at 
the early healing period is decomposed by osteoclast, sub-
stituted to new osteocyte by osteoblast and gradually disap-
peared during the normal healing process.12,18 Recently, 
there was study reporting that empty lacuna was not 
reduced even after administration of  bisphosphonates due 
to suppressed bone remodeling.19,20 In this present study, 
the number of  empty lacuna was significantly increased in 
bisphosphonate group with time, especially in rats sacri-
ficed at 4 weeks after initial administration, which is in line 
with previous study that reported BRONJ like disease.19,20 
This result can be interpreted that suppressed function of  
osteoclast due to administration of  bisphosphonates could 
have led to suppressed bone remodeling and also supported 
by the result of  microarray analysis where up-regulated Sost 
gene, which inhibits bone formation, was identified. Other 
possibility is that this can be due to reduced migration of  
osteoclast, macrophage and monocytes which all act as 
phagocyte, resulted from suppressed angiogenesis due to 
administration of  bisphosphonates. Increased empty lacuna 
which appeared in bone remodeling phase could also be 
related to late failure of  bone remodeling phase after 
implantation. Along the same lines, excessive suppression 
of  bone turnover rate resulting in increased micro-damage 
accumulation has been emerged as a complication of  long-
term bisphosphonates administration.21 It was also reported 
that when microdamage accumulation is increased 2 to 7 
folds, bone toughness is reduced by 20% without any effect 
on bone strength.22 Whyte et al.23 reported the osteopetrosis 
was observed in patient who received pamidronate for 6 
years and spontaneous fracture accompanied by delayed 
fracture was also observed in 9 patients who received alen-
dronates. In addition, bone formation marker was also 
extremely reduced in their histologic analysis. Odvina et al.24 
reported on excessive suppression of  bone turnover fol-
lowing long-term bisphosphonates administration and 
Visekruna et al.25 also addressed that bisphosphonates could 
lead to excessive suppression of  bone turnover rate, result-
ing in unfavorable bone fracture. Therefore, taking these 
studies above as well as the result of  the present study into 
consideration, it can be anticipated that suppression of  
bone turnover rate induced by a long-term use of  bisphos-
phonates could lead to reduced adaptation of  the bone to 
external stimulus, resulting from inactive empty lacunae 
around implant and may be one of  the most contributing 
factors for late implant failure. However,its definitive mech-
anism has not yet been completely clarified. 
The result of  TRAP staining revealed that there was no 
significant difference in the number of  osteoclast between 
control group and bisphosphonate group. The clinical effi-
cacy of  nitrogen-containing bisphosphonates is thought to 
be attributed to reduced number of  osteoclasts from apop-
tosis.26-28 However, it was also reported that the number of  
osteoclast observed in cancellous bone remained unchanged 
following administration of  nitrogen-containing bisphos-
phonates,29,30 which in turn, means that the mechanism of  
bisphosphonates can be different from previous hypothesis. 
There was one study stating that the number of  osteoclast 
increased following alendronates administration in beagle 
dog.31 Weinstein et al.32 also reported the number of  osteo-
clast increased with the increased dose of  alendronates and 
one third of  osteoclasts were found to be giant osteoclasts. 
When the number of  normal osteoclast increases with 
increase in dose of  alendronates, decreased biochemical 
marker and increased bone density may indicate normal 
osteoclast is not playing its role properly in absorption of  
bone. These previous studies showed that nitrogen-contain-
ing bisphosphonates could suppress bone resorption with-
out change in number of  osteocyte and also suggested that 
in cancellous bone, the number of  osteoclast could be 
increased instead. In the present study, there was no signifi-
cant difference in the number of  osteoclast between con-
trol group and bisphosphonate group.
Although it has been defined that bisphosphonates sup-
press formation and function of  osteoclast through many 
previous studies,26-28 the effect of  bisphosphonate on osteo-
blast, which always acts in pair with osteoclast during bone 
remodeling phase, is very scarce. Therefore, in this present 
study, the concentration of  osteocalcin, produced in osteo-
blast and often used as a marker for bone formation was mea-
sured to evaluate the activation and function of  osteoblast.
Immunohistochemical analysis revealed that in both 
control and bisphosphonate groups, the stained osteocla-
cins were observed in the marginal area where bone remod-
eling occur as well as in the cytoplasm of  osteoblast sur-
rounding medullary cavity. There was no significant differ-
ence in the level of  osteocalcin staining between control 
and bisphosphonate groups.33 This result shows that the 
injection of  bisphosphonates has no effect on generation 
and secretion of  osteocalcin. This result is also in agree-
ment with Hirao et al.’s study which evaluated the osteocal-
cin concentration in blood and the bone mineral density of  
femur and cervix from 23 menopausal women who received 
alendronates for one year. In his study, it was reported that 
the administration of  alendronates increased the bone min-
eral density, but had no effect on the concentration of  car-
boxylated osteocalcin in blood.34 
The impairment of  angiogenesis, one of  the possible 
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mechanisms of  BRONJ, was also evaluated in this study by 
observing the level angiopoietin 1, which is thought to be 
associated with blood vessel maturation and stability. In 
contrast to Wood et al.’ study35 where marked antiangiogen-
ic properties of  bisphosphonates had been reported, in this 
study, no significant difference was found between control 
group and bisphosphonate group in the level of  angiopoi-
etin 1. Immunohistochemical analysis also revealed that 
there was no change in the level of  angiopoietin 1. It is 
important to note that from microarray analysis, angiopoi-
etin-like 2, which plays important role in formation of  new 
blood vessel, is down-regulated by half  in bisphosphonate 
group. Therefore, further study may be required to evaluate 
the effect of  bisphosphonate on new blood vessel forma-
tion using angiopoietin-like 2 as well as angiopoietin 1. 
Although limited sample size and short course of  ad-
ministration could have been limitations of  this study, it 
was confirmed that bisphosphonate administration clearly 
had an effect on remodeling of  peri-implant bone. However, 
further study may be required to investigate the definitive 
mechanism of  bisphosphonates which suppress differentia-
tion and activation of  osteoclast without change in its num-
ber and the rationale behind increased number of  empty 
lacunae. Also, in further study, occlusal load applied on 
implant and surrounding bone tissue, which simulate 
patients’ oral condition should be taken into account since 
human bone cell is sensitive to the level of  mechanical 
loading with enhanced release of  cytokine, nitric oxide 
(NO), prostaglandin E2 (PGE2) and various growth fac-
tors,36,37 which may ultimately lead to different results. 
CONCLUSION
Within the limitation of  this study, it can be concluded that 
alendronates administration suppresses bone remodeling, 
resulting in increased metabolically inactive bone cell (emp-
ty lacunae) around implant. 
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